GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXIBF) » Definitions » Net Issuance of Debt

WXIBF (WuXi Biologics (Cayman)) Net Issuance of Debt : $-88 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. WuXi Biologics (Cayman)'s net issuance of debt for the six months ended in Jun. 2024 was $1 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Jun. 2024 was $-88 Mil.

WuXi Biologics (Cayman) Net Issuance of Debt Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Net Issuance of Debt Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 272.30 133.11 -8.32 -24.95 -98.70

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.09 -28.88 -9.64 -89.04 1.15

WuXi Biologics (Cayman) Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXIBF) » Definitions » Net Issuance of Debt
Comparable Companies
HKSE:01801 HKSE:01177 HKSE:01548 HKSE:01877 HKSE:09926 HKSE:09995 HKSE:06990 HKSE:01530 HKSE:06826 HKSE:02162 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX BNTX BGNE
Traded in Other Exchanges
WXXWY:USA 02269:Hong Kong 1FW2:Germany
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
Website
https://www.wuxibiologics.com
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.